Our findings indicate that the anti-inflammatory and antifibrotic effects of eritoran in the NASH model was not attributed to the improvement of hepatic steatosis or insulin resistance, and there may be different sensitivities to eritoran in terms of NF-κB activation in liver parenchymal and nonparenchymal cells. The gene discussed is NFKB1; the disease is fatty liver disease.